The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer

Kebebew, Electron; Weng, Julie; Bauer, Jürgen; Ranvier, Gustavo G. Fernandez; Clark, Orlo H.; Duh, Quan‐Yang; Shibru, Daniel; Bastian, Boris C.; Griffin, A. Clark

doi:10.1097/sla.0b013e318148563d

Cited by 421 publications

(381 citation statements)

References 25 publications

Supporting

Mentioning

341

Contrasting

Unclassified

Order By: Relevance

“…Many studies concluded BRAF mutation is related to aggressive tumor behavior such as extra thyroidal extension, bigger tumor size, lymph node metastasis, advanced disease stage, iodine ablation resistance, and poor disease free survival (Xing et al, 2005;2009a;2009b;Kebebew et al, 2007). Xing et al (2009), showed that analysis of BRAF mutation from FNAB specimens provides a novel tool to identify high risk patients for extensive disease such as extra thyroidal extension and lymph node metastasis and also their study demonstrated a significantly reduced disease free survival in BRAF mutation patients.…”

Section: Discussionmentioning

confidence: 99%

“…Xing et al (2009), showed that analysis of BRAF mutation from FNAB specimens provides a novel tool to identify high risk patients for extensive disease such as extra thyroidal extension and lymph node metastasis and also their study demonstrated a significantly reduced disease free survival in BRAF mutation patients. The other important research was from Kebebew et al (2007), that demonstrated recurrent and persistent diseases were higher even in TNM stage I or AMES low risk classic PTC harboring BRAF mutation. Two studies conducted by Yip et al (2009) andHowell et al (2012) proved that BRAF mutation is related to central lymph node metastasis and they suggest its utility as a guidance to performed the initial extent of surgery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Surgical Perspective of T1799A BRAF Mutation Diagnostic Value in Papillary Thyroid Carcinoma

Brahma

Yulian

Ramli³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Throughout Indonesia, thyroid cancer is one of the ten commonest malignancies, with papillary thyroid carcinoma (PTC) in our hospital accounting for about 60% of all thyroid nodules. Although fine needle aspiration biopsy (FNAB) is the most reliable diagnostic tool, some nodules are diagnosed as indeterminate and second surgery is common for PTC. The aim of this study was to establish the diagnostic value and feasibility of testing the BRAF T1799A mutation on FNA specimens for improving PTC diagnosis. Materials and Methods: This prospective study enrolled 95 patients with thyroid nodules and future surgery planned. Results of mutational status were compared with surgical pathology diagnosis. Results: Of the 70 cases included in the final analysis, 62.8% were PTC and the prevalence of BRAF mutation was 38.6%. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for BRAF mutation analysis were 36%, 100%, 100% and 48%, respectively. With other data findings, nodules with "onset less than 5 year" and "hard consistency" were proven as diagnostic determinants for BRAF mutation with a probability of 62.5%. This mutation was also a significant risk factor for extra-capsular extension. Conclusions: Molecular analysis of the BRAF T1799A mutation in FNAB specimens has high specificity and positive predictive value for PTC. It could be used in the selective patients with clinical characteristics to facilitate PTC diagnosis and for guidance regarding extent of thyroidectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Surgical Perspective of T1799A BRAF Mutation Diagnostic Value in Papillary Thyroid Carcinoma

Brahma

Yulian

Ramli³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The BRAF mutation is found predominantly in PTC, particularly in the conventional and tall cell variants (Cohen et al 2003). Numerous studies have demonstrated a strong association between the BRAF mutation and aggressive clinicopathological characteristics of PTC such as advanced stage, extrathyroidal extension (ETE), lymph node (LN) metastasis and tumor recurrence (Kebebew et al 2007, Lupi et al 2007, Xing 2007. However, there were other studies that did not demonstrate the association between the BRAF mutation and aggressive clinicopathological characteristics of PTC (Lee et al 2012a,b, Gouveia et al 2013, Kim et al 2015.…”

Section: Introductionmentioning

confidence: 92%

Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma

Kim¹,

Woo²,

Lee³

et al. 2015

Endocrine-Related Cancer

View full text Add to dashboard Cite

It has been reported that papillary thyroid carcinoma (PTC) with chronic lymphocytic thyroiditis (CLT) is less associated with extrathyroidal extension (ETE), advanced tumor stage and lymph node (LN) metastasis. Other studies have suggested that concurrent CLT could antagonize PTC progression, even in BRAF-positive patients. Since the clinical significance of the BRAF mutation has been particularly associated with conventional PTC, the purpose of this study was to determine the clinical significance of CLT according to BRAF mutation status in conventional PTC patients. We retrospectively reviewed the medical records of 3332 conventional PTC patients who underwent total thyroidectomy with bilateral central neck dissection at the Thyroid Cancer Center of Samsung Medical Center between January 2008 and June 2015. In this study, the prevalence of BRAF mutation was significantly less frequent in conventional PTC patients with CLT (76.9% vs 86.6%). CLT was an independent predictor for low prevalence of ETE in both BRAF-negative (ORZ0.662, PZ0.023) and BRAF-positive (ORZ0.817, PZ0.027) conventional PTC patients. In addition, CLT was an independent predictor for low prevalence of CLNM in both BRAF-negative (ORZ0.675, PZ0.044) and BRAF-positive (ORZ0.817, PZ0.030) conventional PTC patients. In conclusion, BRAF mutation was significantly less frequent in conventional PTC patients with CLT. However, CLT was an independent predictor for less aggressiveness in conventional PTC patients regardless of BRAF mutation status. Key Words" BRAF mutation " papillary thyroid carcinoma " chronic lymphocytic thyroiditis " central lymph node metastasis " extrathyroidal extension

show abstract

“…Pre-clinical and clinical findings B-Raf mutations have been identified in different cancers, such as melanoma (50-80%), colorectal (11%) and thyroid cancer (45%) (Davies et al, 2002;Domingo et al, 2004;Kebebew et al, 2007;Ziai and Hui, 2012). Regarding NSCLC, B-Raf mutations are detected in 1-2% of these patients, and they are more frequently observed in smokers, almost exclusive of the adenocarcinoma histologic subtype, and the presence of a B-Raf mutation virtually excludes other concomitant driver mutations, such as EGFR, K-Ras or EML4/ALK translocation (Chen et al, 2014;Litvak et al, 2014;Paik et al, 2011).…”

Section: Mutationmentioning

confidence: 99%